



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



FTO (human, recombinant)


Item No. 26340

Overview and Properties

Synonyms:	Fat Mass- and Obesity-Associated Protein, α -Ketoglutarate-dependent Dioxygenase FTO
Source:	Recombinant N-terminal histidine-tagged FTO (32-505) purified from <i>E. coli</i>
Amino Acids:	32-505
Uniprot No.:	Q9C0B1
Molecular Weight:	56.68 kDa
Storage:	-80°C (as supplied)
Stability:	≥ 1 year
Purity:	<i>batch specific</i> ($\geq 80\%$ estimated by SDS-PAGE)
Supplied in:	50 mM HEPES, pH 8.0, with 150 mM sodium chloride and 10% glycerol
Protein Concentration:	<i>batch specific</i> mg/ml

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers
Lane 2: FTO (4 μ g)
Lane 3: FTO (2 μ g)

Representative gel image shown; actual purity may vary between each batch.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/05/2019

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Fat mass and obesity-associated (FTO) protein is a nuclear-residing N⁶-methyladenosine (m⁶A) RNA demethylase that is encoded by the *FTO* gene in humans.¹⁻³ It is composed of an N-terminal domain similar in structure to members of the AlkB non-heme iron-containing dioxygenase family and a C-terminal domain that is not similar to other known domains.⁴ The N-terminal domain contains a loop not found in other AlkB proteins that may be responsible for its specificity for single-stranded nucleic acids. *FTO* is highly expressed during development and in the adult brain, adipose tissue, and muscle and its expression is modified by the availability of essential amino acids *in vitro* and following fasting or a chronic high-fat diet *in vivo* in mice.^{3,5,6} *FTO* regulates mRNA splicing and is required for adipogenesis.^{1,7} Knockdown of *Fto* in mice increases m⁶A-containing transcripts of the adipogenesis-related gene *Runx1t1*, enhances binding of the splicing regulatory protein Srsf2 to *Runx1t1*, which induces the inclusion of *Runx1t1* exon 6 and the production of long *Rnx1t1* transcripts, and leads to inhibition of pre-adipocyte differentiation. *Fto* is associated with obesity in transgenic mouse models, with overexpression increasing food intake and weight gain and knockout reducing body weight, body length, fat mass, and white adipose tissue, as well as increasing energy expenditure while decreasing locomotor activity.² *FTO* SNPs are associated with body mass index and obesity risk in humans.^{6,8}

References

1. Zhao, X., Yang, Y., Sun, B.-F., *et al.* FTO-dependent demethylation of N⁶-methyladenosine regulates mRNA splicing and is required for adipogenesis. *Cell Res.* **24**(12), 1403-1419 (2014).
2. Fischer, J., Koch, L., Emmerling, C., *et al.* Inactivation of the *Fto* gene protects from obesity. *Nature* **458**(7240), 894-899 (2009).
3. McTaggart, J.S., Lee, S., Iberl, M., *et al.* FTO is expressed in neurons throughout the brain and its expression is unaltered by fasting. *PLoS One* **6**(11), e27968 (2011).
4. Han, Z., Niu, T., Chang, J., *et al.* Crystal structure of the FTO protein reveals basis for its substrate specificity. *Nature* **464**(7292), 1205-1209 (2010).
5. Cheung, M.K., Gulati, P., O'Rahilly, S., *et al.* FTO expression is regulated by availability of essential amino acids. *Int. J. Obes. (Lond.)* **37**(5), 744-747 (2013).
6. Gulati, P., Cheung, M.K., Antrobus, R., *et al.* Role for the obesity-related *FTO* gene in the cellular sensing of amino acids. *Proc. Natl. Acad. Sci. USA* **110**(7), 2557-2562 (2013).
7. Ben-Haim, M.S., Moshitch-Moshkovitz, S., and Rechavi, G. FTO: Linking m⁶A demethylation to adipogenesis. *Cell Res.* **25**(1), 3-4 (2015).
8. Loos, R.J.F. and Yeo, G.S.H. The bigger picture of *FTO*: The first GWAS-identified obesity gene. *Nat. Rev. Endocrinol.* **10**(1), 51-61 (2014).